Biomarin Pharmaceuticals (BMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2011 | 09-2011 | 06-2011 | 03-2011 | 12-2010 | |
| Sales | 107,846 | 113,425 | 110,631 | 109,456 | 101,614 |
| Cost of Goods | 21,519 | 22,445 | 19,263 | 20,796 | 20,469 |
| Gross Profit | 86,327 | 90,980 | 91,368 | 88,660 | 81,145 |
| Operating Expenses | 108,281 | 106,942 | 90,863 | 87,162 | 84,964 |
| Operating Income | -21,435 | -15,517 | 768 | 2,294 | -3,350 |
| Interest Expense | 1,877 | 2,168 | 2,201 | 2,163 | 2,746 |
| Other Income | 196 | -2,046 | 260 | 262 | -13,142 |
| Pre-tax Income | -23,116 | -19,731 | -1,173 | 393 | -19,238 |
| Income Tax | 3,619 | -2,078 | 3,904 | 4,764 | -7,049 |
| Net Income Continuous | -26,735 | -17,653 | -5,077 | -4,371 | -12,189 |
| Net Income | $-26,735 | $-17,653 | $-5,077 | $-4,371 | $-12,189 |
| EPS Basic Total Ops | -0.23 | -0.16 | -0.05 | -0.04 | -0.14 |
| EPS Basic Continuous Ops | -0.24 | -0.16 | -0.05 | -0.04 | -0.14 |
| EPS Diluted Total Ops | -0.23 | -0.16 | -0.05 | -0.04 | 0.05 |
| EPS Diluted Continuous Ops | -0.24 | -0.16 | -0.05 | -0.04 | -0.02 |
| EBITDA(a) | $-11,874 | $-5,165 | $10,272 | $11,959 | $5,528 |